Buoyant Life Sciences Sector Emerges Stronger

BioSpectrum Asia’s cover story in its December edition reflects on the advancement and changes that have shaped the industry in 2023. Cartherics’ COO, Dr Ian Nisbet contributed to the article, commenting on the challenges for life sciences companies in the region, particularly smaller and private companies, to raise new capital. He also discussed the impact […]

2023-12-18T10:35:31+11:00December 18th, 2023|

Cartherics grants Shunxi Licence for CAR-T Cell Therapy for Ovarian Cancer in Greater China

Melbourne, Australia, 28 April 2023 –  Cartherics Pty Ltd (“Cartherics”), a biotechnology company developing immune cell therapies for the treatment of cancer, announced today that it has granted Shunxi Holding Group Co Ltd (“Shunxi”) a licence to develop, manufacture and commercialise Cartherics’ autologous CAR-T cell product, CTH-004, for the treatment of multiple solid tumours including […]

2023-04-28T13:00:59+10:00April 28th, 2023|
Go to Top